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Resistance of cancer cells to apoptosis is dependent on a balance of multiple genetic and epigenetic
mechanisms, which up-regulate efficacy of the surviving growth factor-receptor signaling pathways
and suppress death-receptor signaling pathways. The Insulin-likeGrowth Factor-1Receptor (IGF-1R)
signaling pathway is highly active inmetastaticmelanoma cells bymediating downstream activation
of PI3K-AKTandMAPKpathways and controlling general cell survival andproliferation. In thepresent
study, we used humanmelanoma lines with established genotypes that represented different phases
of cancer development: radial-growth-phase WM35, vertical-growth-phase WM793, metastatic
LU1205andWM9 [1]. All these lines havenormalNRAS.WM35,WM793, LU1205andWM9cells have
mutated BRAF (V600E). WM35 and WM9 cells express normal PTEN, while in WM793 cells PTEN
expression is down-regulated; finally, in LU1205 cells PTEN is inactivated by mutation. Cyclolignan
picropodophyllin (PPP), a specific inhibitor of IGF-1R kinase activity, strongly down-regulated the
basal levels of AKT activity inWM9and inWM793 cells,modestly does so in LU1205, but has no effect
on AKT activity in the early stage WM35 cells that are deficient in IGF-1R. In addition, PPP partially
down-regulated the basal levels of active ERK1/2 in all lines used, highlighting the role of an
alternative, non-BRAFpathway inMAPKactivation. The final result of PPP treatmentwas an induction
of apoptosis in WM793, WM9 and LU1205 melanoma cells. On the other hand, dose-dependent
inhibition of IGF-1R kinase activity by PPP at a relatively narrow dose range (near 500 nM) has
different effects onmelanoma cells versus normal cells, inducing apoptosis in cancer cells and G2/M
arrest of fibroblasts. To further enhance the pro-apoptotic effects of PPP onmelanoma cells,we used a
combined treatment of TNF-Related Apoptosis-Inducing Ligand (TRAIL) and PPP. This combination
substantially increased death by apoptosis for WM793 and WM9 cells, but did so only modestly for
LU1205 cells with very high basal activity of AKT. The ultimate goal of this direction of research is the
discovery of a new treatmentmethod for highly resistant humanmetastaticmelanomas. Our findings
provide the rationale for further preclinical evaluation of this novel treatment.
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Introduction
Melanoma, the deadliest form of skin cancer, is often markedly
resistant to treatments using conventional radiotherapy or che-
motherapy. Because of this widespread resistance, the metastatic
stage of melanoma is almost incurable [2]. The U.S. Food and Drug
Administration approved the only anti-metastatic melanoma drug,
dacarbazine, in 1975. During the last two decades, enormous
efforts have beenundertaken to increase the effectiveness of cancer
treatments, including those for metastatic melanoma, through the
induction of programmed cell death by apoptosis [3]. TNF-Related
Apoptosis Inducing Ligand (TRAIL) is particularly attractive for
anti-cancer treatment due to its low toxicity and synergy with
conventional cancer therapies [4,5]. While early clinical trials have
found no single-agent activity of TRAIL in lung cancer [6], pre-
clinical work has suggested that TRAIL may work synergistically
with conventional therapies to improve cancer outcomes [7], and
several clinical trials are currently underway testing this approach.
Additionally, various methods have been used to sensitize cancer
cells to TRAIL-induced apoptosis, with some promising results [8].
Most melanoma cells demonstrate resistance to TRAIL through
multiple genetic and epigenetic mechanisms that suppress death
signaling pathways and promote cell survival. Notably, PI3K-AKT,
MEK-ERK, IKK-NF-κB, JAK2-STAT3 and ATM signaling pathways,
which are critically involved in the regulation of cell proliferation,
cell survival and protection against apoptosis, are often up-
regulated in metastatic melanoma cells and showed a marked
propensity for preventing of cell death [9–11].
As with the various apoptosis activators such as TRAIL and Fas
Ligand, the corresponding inhibitors of cell survival signaling
pathways have been the subject of widespread study for cytostatic
and anti-cancer activities. In previous studies, we and others
demonstrated the relatively modest effects of small molecular
inhibitors of the MEK-ERK and PI3K-AKT signaling pathways on
the induction of apoptosis in human melanoma cells; in contrast,
the combined targeting of both of these pathways resulted in
substantial acceleration of cancer cell death [12,13]. Growth factor
receptor kinase activity is an upstream regulator of the MEK-ERK
and PI3K-AKT signaling pathways. The IGF-1 Receptor (IGF-1R)-
mediated signaling pathway is in the control of numerous
functions in normal mammalian embryogenesis and postnatal
development, tissue growth and general metabolism. Insulin and
Insulin-like growth Factors (IGF-1/2), together with IGF-1 Recep-
tor, have been increasingly shown to have important roles
in neoplasia [14,15]. Cleavage and processing of the precursor
pro-receptor (230 kDa) produces a 135 kDaα-subunit and a 95 kDa
β-subunit. The IGF-1 Receptor complex contains two extracellular
ligand binding α-subunits and two β-subunits that contain an
extracellular, a transmembrane, an intracellular tyrosine kinase and
a C-terminal domain. IGF-1/IGF-2 binding induces autophosphor-
ylation of IGF-1Rβ, activation of its kinase activity and initiation of
the downstream signaling cascades: N-RAS–B-RAF/C-RAF–MEK–
ERK and PI3K–AKT–GSK3β or PI3K–AKT–mTOR [16].
IGF-1 is a critical factor for growth of many types of cancer,
including melanomas, while inhibitors of IGF-1R-mediated signal-
ing suppress the downstream PI3K-AKT and MAPK pathways,
suggesting a strong pro-apoptotic activity for these inhibitors for
some types of cancer [17,18]. However, as a result of Darwinian
selection, many melanoma cell lines and original tumor samples
possess signal activating mutations in transduction modules
downstream to growth factor receptors, including the IGF-1
receptor, providing a partial autonomy from the growth factor
stimulation. Activating mutations in NRAS are found in 33% of
primary and 26% of metastatic tumors, BRAF activating mutations
were identified in a variety of melanoma cell lines and up to 67% of
melanoma tumor samples [19,20]. Mutations in CRAF are relatively
rare [21]. It is of note that BRAF (V600E) and NRAS mutations are
mutually exclusive in melanomas. On the other hand, PTEN, tumor
suppressor and an inhibitor of the PI3K-AKT pathway is also
mutated and inactivated in 20-40% of melanoma lines, but
infrequently in the melanoma tumor samples, resulting in up-
regulation of the PI3K-AKT pathway [22]. BRAF and PTEN
mutations are found concurrently in 20% of melanoma lines [23].
It should be highlighted that in spite of a partial independence of
the MAPK pathway and the PI3K-AKT pathway from the upstream
signaling in mutated melanoma lines, these cell lines often need
certain level of growth factor (IGF-1/2, insulin, HGF or FGF2)
stimulation via autocrine or paracrine mechanisms and a possible
additional usage of the C-RAS bypass for effective growth [1].
Deregulation of these signaling pathways may occur not only
through described mutations in NRAS, BRAF and PTEN, but also via
up-regulation of expression levels and activation of IGF-1R, a
characteristic feature of several types of tumors, including
melanoma [15]. Multiple attempts were performed to suppress
IGF-1R-mediated signaling in cancer cells using different
approaches, including anti-sense RNA [24], siRNA [25], small
molecular inhibitors [26] and antagonistic monoclonal antibodies
[27]. Recently, drugs that block the signaling action of IGF family
members have been found to have anti-tumor action [18,28,29].
Regulation of IGF-1R protein function through modification
may occur not only by specific autophosphorylation, but also
through SUMOylation and the nuclear translocationwheremodified
IGF-1R plays a role for transcriptional regulation [30], demonstrating
an alternative mechanism for IGF-1R to control carcinogenesis.
Melanoma cells do not express endogenous IGF-1/IGF-2 at
notable levels, instead receiving these signaling ligands from
fibroblasts in the microenvironment or through the bloodstream
[17,31]. While the effects of both TRAIL agonists and IGF/IGF-1R
antagonists are undergoing current clinical study separately,
evidence linking their mechanisms for action suggests that they
may act efficiently in combination to induce cell death. In other
words, by blocking the actions of IGF-mediated survival signals, it
may be possible to increase the efficacy of TRAIL and establish the
induction of apoptosis as amore viable treatment pathway. Results
of the present study indeed confirm the high efficacy of TRAIL and
a IGF-1R-kinase inhibitor combination for killing human melano-




Cycloheximide (CHX) was obtained from Sigma (St. Louis, MO,
USA). Human soluble Killer-TRAIL (recombinant) and human
soluble Fas Ligand (recombinant) were purchased from Alexis
(San Diego, CA, USA). IGF-1R kinase inhibitor picropodophyllin
(PPP), PI3K inhibitor LY294002, MEK inhibitor U0126, MAPK p38
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inhibitor SB203580 and caspase inhibitor zVAD-fmk were pur-
chased from Calbiochem (La Jolla, CA, USA).
Cell lines
Several human melanoma cell lines were used: WM35 is a radial-
growth-phase melanoma cells; WM793 is a vertical-growth-phase
melanoma cells; LU1205 (also known as 1250lu) and WM9 are
metastatic melanoma cells. All four melanoma lines have normal
NRAS. WM35, WM793, LU1205 and WM9 cells have mutated BRAF
(V600E).WM35andWM9express functional PTEN,while inWM793
cells PTENexpression is down-regulated; finally in LU1205cells PTEN
is inactivated by mutation [1,21,32–35]. Several human fibroblast
lines were used: IMR-90, the primary human embryonic lung
fibroblasts; TIG3, immortalized human embryonic lung fibroblasts;
and HSF, human skin fibroblasts immortalized by SV40 T antigen. All
cell lines, besides IMR-90, were maintained in DMEM medium,
supplemented with 10% fetal bovine serum, L-glutamine and
antibiotics. IMR-90 cells were maintained in medium supplemented
with 15% fetal bovine serum, vitamins, non-essential amino acids and
antibiotics.
FACS analysis of TRAIL and TRAIL-R2/DR5 levels
Surface levels of TRAIL-R1/DR4 and TRAIL-R2/DR5 on human
melanomas were determined by staining with PE-conjugated anti-
human DR4 or anti-human DR5mAbs (eBioscience, San Diego, CA)
and subsequent flow cytometry. PE-conjugated nonspecific mouse
IgG1 was used as an immunoglobulin isotype control. A FacsCa-
libur flow cytometer (Becton Dickinson, Mountain View, CA)
combined with the CellQuest program was used to perform flow
cytometric analysis. All experiments were independently repeated
3-5 times.
Apoptosis studies
Cells were exposed to TRAIL (50 ng/ml) alone, PPP (250 nM-2 μM)
alone, and a combination of TRAIL and PPP in order to determine
the relative rates of apoptosis. Apoptosis was quantified as the
percentage of hypodiploid (pre-G1) nuclei undergoing DNA
fragmentation using PI staining and the flow cytometry (a FACS
Calibur flow cytometer).
Cell proliferation assay
Cell were plated in six-well plates and allowed to attach for 24 h
prior to the addition of DMSOor PPP to the culturemedium (day 0).
In some experiments, TRAILwas added to the culturemediumafter
additional 24 h (day 1). Cell cultures were trypsinised and counted
at day 0, day 1, day 2 and day 3 using a Coulter counter.
Clonogenic survival assay
Cells were exposed to soluble TRAIL (50 ng/ml) alone or in
combination with CHX (1 μg/ml), PPP (250 nM -2 μM) alone or in
combination with TRAIL for 24 h. Treated cells (500/dish) were
then placed in duplicate on 10-cm dishes for analysis of clonogenic
survival 12 days after treatment. Colonies were stained using
crystal violet solution. The percentage of colony-formation (in
relation to values for untreated control cells) was calculated.
Western blot analysis
Total cell lysates (50 μg protein) were resolved on SDS-PAGE, and
processed according to standard protocols. The monoclonal anti-
bodies used for Western blotting included: anti-β-Actin (Sigma);
anti-caspase-3; anti-ATM (D2E2) and anti-phospho-ATM
(Ser1981); anti-phospho-IGF1-Receptor β (Tyr1135/11360). The
polyclonal antibodies used included: anti-phospho-SAPK/JNK
(Thr183/Tyr185) and anti-JNK; anti-phospho-p44/p42 MAP kinase
(Thr202/Tyr204) and anti-p44/p42MAP kinase; anti-phospho-AKT
(Ser473) and anti-AKT; anti-PARP; anti-STAT3, anti-phospho-STAT3
(Tyr705) and anti-phospho-STAT3 (Ser727); anti-IGF-1 receptor β
(Cell Signaling). The secondary Abs were conjugated to horse-
radish peroxidase; signals were detected using the ECL system
(Amersham). Comparisons of the levels of the active phosphorylated
proteins were made at several concentrations of PPP in order to
elucidate the molecular pathway of its action.
Statistical analysis
Data was calculated using means and standard deviations. Compar-
isons of surviving fractions was made using Students’ t-tests, with a
p-value of 0.05 or less considered significant.
Results
Inhibition of the cell signaling pathways in normal and
melanoma cells by PPP
The first aim of the present study was to evaluate effects of
inhibition of the IGF-1R-mediated signaling pathway on the
regulation of cell cycle arrest and apoptosis in human melanoma
cell lines representing different phases of tumor development. We
used WM35, a horizontal-growth-phase human melanoma line,
WM793, a vertical-growth- phase human melanoma line, as well
as LU1205 and WM9 human metastatic melanoma lines [36]. All
four melanoma lines possess activating BRAF (V600E) mutation
that results in up-regulation of the basal MEK-ERK1/2 activity.
WM35 and WM9 cells express functional PTEN, while in WM793
cells PTEN expression is down-regulated; finally, in LU1205 cells
PTEN is inactivated by mutation that was accompanied by a strong
increase in the basal AKT activity [21,32–35,37]. Furthermore, we
used as controls several human fibroblast lines: IMR-90, TIG-3 and
HSF. Human melanoblasts, which required highly activating
conditions for their growth in culture, could not be used as an
adequate control for this type of experiment.
To further confirm amajor role of IGF-1R-mediated signaling in
the activation of the downstream AKT signaling pathways and in
the regulation of cell cycle in human melanoma cells, we used
picropodophyllin (PPP), a specific inhibitor of IGF1-R-mediated
signaling that blocks the critical Tyr1135 autophosphorylation of
the IGF-1-R β-subunit and suppresses its kinase activity [26].
Furthermore, prolonged treatment by PPP caused down-regula-
tion of IGF-1R protein levels via its enhanced degradation [38].
IMR-90, human embryonic lung fibroblasts with non-detectable
IGF-1R activation, did not specifically respond to PPP treatment
(0.5 μM). Very low levels of phospho-ERK, phospho-AKT, and
phospho-GSK3α were unchanged, and no growth arrest was
observed for IMR-90 cells under these conditions (Figs. 1A and B),
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Fig. 1 – Effects of picropodophyllin (PPP) on IGF-1-mediated signaling pathway in human fibroblasts. A. Western blot analysis of
indicated proteins 4 h after treatment of IMR-90 embryonic lung fibroblasts with PPP (0.5 μM). B. Effects of PPP on cell cycle of IMR-90
24 h after treatment. Cells were stained by PI 24 h after indicated treatment and analyzed by the flow cytometry. % Cells at the distinct
phases of the cell cycle is indicated. Results of typical experiments (one of four) are presented. C. Western blot analysis of indicated
proteins 4 h after treatment of human skin fibroblasts (HSF) with PPP (0.25-0.5 μM). D. Effects of PPP on cell cycle of HSF 24 h after
treatment.
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while further cell proliferation was detected (data not shown). On
the other hand, for the transformed human skin fibroblasts (HSF),
down-regulation of IGF1-R kinase activity by 0.5 μM PPP was
accompanied by the expected decrease in the phosphorylation
of AKT and its downstream target, GSK3β, and by the parallel
decrease in phospho-ERK1/2 levels (Fig. 1C). Interestingly, PPP at
doses 0.25 - 1 μM PPP efficiently induced G2/M arrest of HSF 24 h
after treatment (Fig. 1D).
Four hours after treatment, PPP (0.5 μM) caused a strong
decrease in phospho-(Tyr1135/1136) levels of both the precursor
(230 kDa) and the mature (95 kDa) β-subunit of the IGF-1
receptor in WM9 metastatic melanoma cells (Fig. 2A). In non-
treated WM35 radial-growth-phase melanoma cells, IGF-1R was
present mainly as the precursor form. Paradoxically, 0.5 μM PPP
induced an appearance of the mature 95 kDa β-subunit with some
level of phosphorylation in these cells (Fig. 2A). As expected, an
inhibition of IGF1-R kinase activity by PPP was accompanied by
down-regulation of the levels of the active AKT-P-(Ser473) in
WM9 cells. Furthermore, a partial down-regulation of ERK1/2-P-
(Thr202/Tyr204) levels was also observed (Fig. 2A). In contrast,
for WM35 cells, 0.25-0.5 μM PPP did not affect AKT activation, but
still down-regulated ERK1/2 phosphorylation, highlighting a
partial functionality of the IGF-1-induced signaling pathways in
the early melanoma cells (Fig. 2A). A decrease in ERK1/2
phosphorylation levels by PPP in melanoma cells with activating
BRAF (V600E) suggested the involvement of CRAF in ERK
activation. WM9 cells, furthermore, possess notable basal levels
of active MAPK p38, which were also strongly down-regulated by
0.5 μM PPP 4 h after treatment (Fig. 2A).
A characteristic aspect of apoptotic commitment, caspase-3
activation via the cleavage of pro-caspase-3 (32 kDa), was
detected in WM9 cells following PPP treatment, while the basal
level of pro-caspase-3 was very low in the WM35 early melanoma
cells. The remarkable feature of the prolonged 24 h treatment with
PPP was a caspase-mediated cleavage of ATM, an enzyme
controlling numerous pro-survival and anti-apoptotic functions,
in WM9 cells and dose-dependent down-regulation of ATM
protein levels in the WM35 cells (Fig. 2B). In contrast, levels of
anti-apoptotic proteins, Survivin and Smac, were relatively stable
after PPP treatment (Fig. 2B). Hence, prolonged PPP treatment
initiated apoptotic commitment in WM9 metastatic cells, but only
suppressed some protein regulators of cell survival in WM35 early
melanoma cells.
Down-regulation of the AKT activity by PPP was also observed
in WM793 with intermediate levels of the basal AKT activity. In
contrast, for LU1205 cells with increased levels of the basal AKT
activity, due to PTEN inactivation, PPP at dose 0.5 μM only
modestly decreased AKT and ERK1/2 activities (Fig. 2C).
Dose-response effects of PPP on inhibition of melanoma cell
growth and induction of apoptosis
Based on the functional specificity of PPP treatment, we deter-
mined its dose-dependent effects on cell cycle and growth of
normal fibroblasts and melanoma cells in culture. We found that
0.5-2 μM PPP efficiently induced G2/M arrest of human skin
fibroblasts (Fig. 1D) and TIG-3 fibroblasts (Fig. 3), while initiating
apoptosis in WM793, LU1205 andWM9melanoma cells in a dose-
dependent manner 24 h after treatment (Fig. 3). The early WM35
melanoma cells demonstrated a dual response: G2/M arrest at PPP
a dose of 0.5-1 μM and pronounced apoptosis with 2 μM PPP 24 h
after treatment (Fig. 3).
PPP at dose 0.5-1 μM completely blocked growth of fibroblast
and melanoma cell cultures (vertical-growth-phase WM793 and
metastatic LU1205 and WM9 lines), with the exception of radial-
Fig. 2 – Effects of PPP on IGF-1-mediated signaling pathway in
melanoma cells. A-C.Westernblot analysiswas performed4-24 h
after treatment of WM35 and WM9 or LU1205 and WM793
melanoma cells with indicated doses of PPP. Analyzed proteins
are indicated.
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growth-phase WM35 melanoma cells, which required at least
2 μM PPP for growth arrest (Fig. 4 and data not shown). Growth of
IMR-90, normal embryonic lung fibroblasts with defective IGF-1R-
mediated signaling, was not affected by PPP at the dose range of
0.5-2 μM (Fig. 1B and data not shown).
PPP decreases cellular survival in a dose-dependent manner
Clonogenic survival assays after PPP treatment generally correlated
with the cell cycle results measuring the induction of melanoma
apoptosis, but also demonstrated non-apoptotic, probably, necrotic
cell death for normal fibroblasts 12 days after treatment (Fig. 5).
Values of total levels of cell death, however, indicated that the TIG-3
normal fibroblasts were more resistant to the 250 nM and 500 nM
doses of PPP than were the melanoma cells (Fig. 5). HSF were
modestly resistant to PPP (500 nM -1 μM) compared to melanoma
cells (data not shown). The primary IMR-90 fibroblasts, which
demonstrated high resistance to PPP in the cell cycle analysis
experiments (Fig. 1B), did not form colonies in the clonogenic
survival assay. When combined with the cell cycle results, this
narrow window of PPP doses near 500 nM that had more
pronounced negative effects on the survival ofmetastaticmelanoma
cells as compared to that of normal fibroblasts.WM9melanoma cells
demonstrated substantially higher sensitivity to PPP, compared to
LU1205 cells with increased levels of AKT activity.
Fig. 4 – Dose-dependent effects of PPP on the cell growth of the normal (TIG3), transformed (HSF) and cancer (WM35, WM793,
LU1205, WM9 melanoma) cell lines. PPP was dissolved in DMSO; the final concentration of DMSO in the medium was 0.1%.
Fig. 5 – Clonogenic survival assay of fibroblasts and melanoma
cell lines 12 days after treatmentwith PPP. Error bars represent
mean±S.D. from three independent experiments (Student's
t test, P<0.05).
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PPP sensitizes melanoma cells to TRAIL-mediated apoptosis
The main objective for treatments that induce apoptosis in cancer
cells is maximizing the specific killing of those with little toxic
effect for normal cells. Although PPP treatment resulted in
pronounced differences between the death of normal fibroblasts
and metastatic melanoma cells, levels of cancer cell death were
still well below 100%. A complementary co-treatment was
required to achieve this critical task. Normal human fibroblasts,
including TIG-3, are known to have very low surface expression of
TRAIL-R2/DR5 and TRAIL-R1/DR4, exhibiting high resistance to
TRAIL (Fig. 6A). On the other hand, our previous studies
demonstrated intermediate to high levels of surface expression
of DR5 on many melanoma cells (Fig. 6A), while DR4 surface
expression was, as a rule, very low or negligible in these cells [10].
Transformed human skin fibroblasts (HSF) demonstrated also
intermediate levels of surface DR5 expression. However, most
melanoma lines are relatively resistant to TRAIL alone and need
additional sensitization through the blockage of cell survival
pathways [8]. Interestingly, WM793 vertical-growth-phase and
WM9 metastatic melanoma cells are sensitive to TRAIL treatment
and exhibited a dose-dependent response for 10-100 ng/ml of
TRAIL alone (Supplementary Fig. 1). We selected a dose of TRAIL
(50 ng/ml) that could kill approximately 40% of these sensitive
melanoma cells for further study in combined treatments.
Combined treatment of TRAIL (50 ng/ml) and PPP, which has
been used in the present study, resulted in a substantial increase
in the levels of apoptosis for vertical-growth-phase WM793 and
for metastatic WM9 melanoma cells, as measured by FACS
analysis of sub-G1 levels. LU1205 metastatic melanoma cells
with high levels of AKT activity and low sensitivity to TRAIL alone
demonstrated a relatively modest increase in apoptotic levels after
combined treatment with TRAIL and PPP. The early melanoma
cells WM35 with low DR5 surface expression showed also limited
sensitivity to TRAIL, while the primary fibroblasts IMR-90 showed
virtually no sensitivity to either TRAIL or PPP (Fig. 6B with a
typical experiment and Fig. 7A with data for 4 independent
repeats of this experiment). A combination of TRAIL (50 ng/ml)
and a protein synthesis inhibitor, cycloheximide (CHX, 4 μM), also
induced high levels of apoptosis in WM793 and WM9 cells, but
intermediate levels in LU1205 cells. PPP co-treatment still
modestly increased levels of TRAIL+CHX induced apoptosis for
WM35 cells, but not for LU1205 cells (Fig. 7B). However, a
substitution of LY294002, an efficient inhibitor of the PI3K-AKT
pathway, for PPP dramatically increased the apoptosis induced by
TRAIL+CHX in LU1205 cells (Figs. 7C and D), further highlighting
a role for PI3K-AKT for suppression of TRAIL-induced apoptosis.
Transformed HSF demonstrated increased apoptosis after treat-
ment with a combination of TRAIL and PPP and, especially, TRAIL
and CHX (Fig. 7). PPP was also able to accelerate FasL-induced
apoptosis of melanoma cells, albeit less efficiently than TRAIL-
induced apoptosis (Fig. 6B).
Results of the proliferation assay further indicated that
combined treatment by TRAIL (50 ng/ml and 25 ng/ml) and PPP
(250 nM) strongly suppressed WM793 and WM9 melanoma cell
proliferation in culture demonstrating a high efficacy of such
combined treatment for cancer cells with regulated PI3K-AKT
activity (Fig. 8). We have used TIG3 normal human fibroblasts as
the control line. PPP alone induced G2/M arrest of TIG3 fibroblasts
without pronounced toxicity (see Fig. 3). These cells are relatively
insensitive to TRAIL treatment and combined treatment of TRAIL
and PPP had no additive effects. In contrast, WM793 cells, which
are sensitive to TRAIL (50 ng/ml and 25 ng/ml) and PPP (250 nM),
demonstrated pronounced additive effects for combined treat-
ment. For WM9 cells accelerated effects of combined treatment
might be observed between day 1 and 3 for TRAIL dose at 25 ng/ml
(Fig. 8).
The clonogenic survival assay confirmed the enhanced effec-
tiveness of killing melanoma cells using combined treatment with
TRAIL (50 ng/ml) and PPP (250-500 nM) that was more effective
compared to results of killing by TRAIL alone (Figs. 9A and B). More
than 90% of WM9 and WM793 cells were killed by a combination
of TRAIL and PPP (Fig. 9B). Surprisingly, nearly 80% of resistant
LU1205 metastatic melanoma cells were also killed. This may
indicate a mix of apoptotic and non-apoptotic death pathways
induced by prolonged treatment of PPP and TRAIL in LU1205 cells.
The early melanoma WM35 cells were quite resistant to killing by
a combination of TRAIL+PPP, as well as by TRAIL+CHX (Fig. 9). It
should also be highlighted that the optimal concentration of PPP
(0.5 μM) for treatment in combination with TRAIL was substan-
tially lower than for CHX (4 μM). Taken together, the results
obtained in this study demonstrated a predictably variable
apoptotic response of human melanoma cells to PPP, TRAIL and
its combination.WM9 andWM793 cells were efficiently killed by a
combined treatment, while LU1205 cells demonstrated a certain
resistance to apoptosis, due to high basal AKT activity, which could
be overcome by an additional inhibition of AKT activation. On the
other hand, WM35 cells with a deficiency in IGF-1R expression
also exhibited only a modest response to combined treatment.
Discussion
Metastatic melanoma is one of the most refractory cancers to
treat. The main signaling pathways regulating cell survival, PI3K-
AKT, BRAF-MEK-ERK, IKK-NF-κB and JAK2-STAT3, are highly
active in metastatic melanoma cells, providing strong resistance
to apoptotic signaling [9,39]. This activation is based on multiple
genetic and epigenetic mechanisms, including activating muta-
tions of NRAS [40], frequent deletion of PTEN, an endogenous
inhibitor of the PI3K-AKT pathway [22], a mutation in BRAF
(V600E) that permanently activates the downstream MAPK
pathway [19,41], genomic amplification of IKBKB chromosome
area [42] and additional epigenetic regulation of the IKK-NF-κB
[43] and JAK2-STAT3 [44] pathways in human melanoma cells.
During the last decade, tremendous efforts have been undertaken
to create and investigate specific inhibitors of these pathways to
block tumor growth. Multiple clinical trials with specific pharma-
cological inhibitors and antagonistic monoclonal antibodies are in
progress now. However, the usage of inhibitors of the certain
signaling pathway may results in the dramatic and undesirable
induction of the bypass signaling pathway. Thus, RAF inhibitors
are selective in inhibiting proliferation of BRAF (V600E) cancer cell
lines, but activate the MAPK pathway in non-BRAF (V600E) cells in
CRAF-dependent manner. It could potentially induce CRAF in
normal tissues and non-BRAF (V600E) tumors during treatment
[45].
An alternative approach for the treatment of melanoma is based
on the specific induction of apoptosis in cancer cells via death
receptor-mediated pathways. Fortunately, many metastatic
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melanomas exhibit the surface expression of TRAIL-R2/DR5,
creating a possibility for therapy. However, to improve the clinical
applicability, an additional treatment to block cancer cell survival
functions is needed in order to substantially enhance TRAIL-
mediated apoptosis in melanoma cells. We and others have
previously used sodium arsenite [46], resveratrol [8], ATM inhibitors
Fig. 7 – A, B andC. Apoptotic cell deathafter combined treatmentwith TRAIL+PPP, TRAIL+CHX , TRAIL+CHX+PPPor TRAIL+CHX+
LY294002 in indicated normal and cancer (melanoma) cell lines. TRAIL (50 ng/ml), CHX (4 μM) and LY294002 (50 μM) and indicated
doses of PPPwere usedwith. Error bars representmean±S.D. for four independent experiments (Student's t test, P<0.05). D.Western
blot analysis of active and total AKT levels in LU1205 cells 6 h after treatment with LY294002 (50 μM).
Fig. 6 – TRAIL-mediated apoptotic signaling in humanmelanoma cells. A. Surface expression of TRAIL-R2/DR5 in indicated cell lines
cells was determined by immunostaining using PE-labeled mAb and the FACS analysis. Medium fluorescent intensity (MFI) is
indicated. B, C. Apoptosis in WM9metastatic melanoma cells after treatment by PPP, TRAIL, FasL or combination ether PPP+TRAIL
(50 ng/ml) or PPP+FasL (50 ng/ml). Results of a typical experiment are presented. Apoptosis (Apop) levels were determined as the
percentage of cells with hypodiploid content of DNA in the pre-G0/G1 region using flow cytometry.
2003E X P E R I M E N T A L C E L L R E S E A R C H 3 1 6 ( 2 0 1 0 ) 1 9 9 4 – 2 0 0 7
Author's personal copy
[10], IFN-β [47], tunicamycin [48] and several other agents targeting
cell surviving pathways [11] to sensitize melanoma cells to TRAIL-
induced apoptosis.
The main target of the approach used in the present study was
IGF-1R-mediated signaling pathway that was specifically blocked by
PPP before TRAIL action. Such inhibition could be an efficient way to
suppress, partially or completely, the downstream PI3K-AKT and
MAPKpathway, depending on the genotype of the cancer cell clones.
We demonstrated in the present study that pre-treatment was
especially efficient formelanoma lineswith lowormodest basal AKT
activity (without PTEN inactivated mutation) and resulted in a
strong up-regulation of TRAIL-mediated apoptosis after a combined
treatment. In recent years, PPP treatment was successfully used for
the induction of apoptosis in several cancer models [49,50]. While
both PPP [51,52] and TRAIL [5,53] are still in early-stage clinical trials
and much remains to be determined about their single-agent
efficacy, our data suggest that combination therapy using these
two drugs may prove to be a more effective approach. Whereas
currentmelanoma therapies rely on broad-based cellular damage to
induce cell death using both necrosis and apoptosis, these new
approaches work through specific receptor-mediated signaling
pathways, making them more able to preferentially target cancer
Fig. 8 –Dose-dependent effects of PPP (250-500 nM) and TRAIL (25 and 50 ng/ml) alone or in combination on the cell growth of TIG3
normal human fibroblasts andWM35 andWM9melanoma cell lines. PPPwas dissolved in DMSO; the final concentration of DMSO in
the medium was 0.1%. PPP was added to the cell media at day 0, TRAIL was added at day 1. Error bars represent mean±S.D. from
three independent experiments (Student's t test, P<0.05).
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cells but also more vulnerable to intercellular genomic diversity. By
both activating the extrinsic death pathway using TRAIL and
disabling the IGF-1R-dependent survival pathways using PPP, we
have substantially increased the therapeutic ratio of treatment-
sensitive melanoma cells.
In addition to testing our current regimen, we also hoped to
better understand the molecular mechanisms through which PPP
works to discover other potential therapeutic targets. One critical
observation was the confirmation of the connection of IGF-1R-
mediated signaling with the activation of ATM [54], a significant
regulator of radioresistance (Fig. 1B), as previously observed [39].
Treatment of human melanoma cells with PPP induced apoptotic
signaling pathways and resulted in the cleavage and degradation
of ATM that was accompanied by a substantially increased
radiosensitivity in the metastatic melanoma cells (non-published
observation). Cleavage and inactivation of ATM during TNFα-
induced apoptotic commitment was also previously reported [55].
Interestingly, in our recent paper we demonstrated a dramatic up-
regulation of TRAIL-mediated apoptosis by inhibition of ATM [10].
Our current studies confirmed and expanded these observations
by using a combination of recombinant TRAIL and the IGF-1R
inhibitor PPP that also substantially up-regulated TRAIL-mediated
apoptosis. While numerous barriers remain before we can suggest
this specific regimen as a treatment, our progress thus far suggests
that apoptosis-inducing melanoma treatments are a viable
approach [10].
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Fig. 9 – A. Clonogenic survival assay of indicated melanoma cell lines 12 days after treatment with different concentration of TRAIL
alone. B. Clonogenic survival assay of indicated melanoma cell lines 12 days after indicated treatments with PPP, TRAIL (50 ng/ml),
PPP+TRAIL, CHX (4 μM), CHX+TRAIL. Error bars represent mean±S.D. for three independent experiments (Student's t test,
P<0.05).
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